The c.156_157insAlu BRCA2 mutation has so far only been reported in hereditary breast/ovarian cancer (HBOC) families of Portuguese origin. Since this mutation is not detectable using the commonly used screening methodologies and must be specifically sought, we screened for this rearrangement in a total of 5,443 suspected HBOC families from several countries. Whereas the c.156_157insAlu BRCA2 mutation was detected in 11 of 149 suspected HBOC families from Portugal, representing 37.9% of all deleterious mutations, in other countries it was detected only in one proband living in France and in four individuals requesting predictive testing living in France and in the USA, all being Portuguese immigrants. After performing an extensive haplotype study in carrier families, we estimate that this founder mutation occurred 558 +/- A 215 years ago. We further demonstrate significant quantitative differences regarding the production of the BRCA2 full length RNA and the transcript lacking exon 3 in c.156_157insAlu BRCA2 mutation carriers and in controls. The cumulative incidence of breast cancer in carriers did not differ from that of other BRCA2 and BRCA1 pathogenic mutations. We recommend that all suspected HBOC families from Portugal or with Portuguese ancestry are specifically tested for this rearrangement.
International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation / Ana, Peixoto; Catarina, Santos; Manuela, Pinheiro; Pedro, Pinto; Maria Jose, Soares; Patricia, Rocha; Leonor, Gusmao; Antonio, Amorim; A., Van Der Hout; Anne Marie, Gerdes; Mads, Thomassen; Torben A., Kruse; Dorthe, Cruger; Lone, Sunde; Yves Jean, Bignon; Nancy, Uhrhammer; Lucie, Cornil; Etienne, Rouleau; Rosette, Lidereau; Drakoulis, Yannoukakos; Maroulio, Pertesi; Steven, Narod; Robert, Royer; Maurício M., Costa; Conxi, Lazaro; Lidia, Feliubadalo; Begona, Grana; Ignacio, Blanco; M., De La Hoya; Trinidad, Caldes; Philippe, Maillet; Gaelle Benais, Pont; Bruno, Pardo; Yael, Laitman; Eitan, Friedman; Eladio A., Velasco; Mercedes, Duran; Maria Dolores, Miramar; Ana Rodriguez, Valle; Maria Teresa, Calvo; Ana, Vega; Ana, Blanco; Orland, Diez; Sara Gutierrez, Enriquez; Judith, Balmana; Try, Cajal; Carmen, Alonso; Montserrat, Baiget; William, Foulkes; Marc, Tischkowitz; Rachel, Kyle; Nelly, Sabbaghian; Patricia Ashton, Prolla; Ingrid P., Ewald; Thangarajan, Rajkumar; Luisa Mota, Vieira; Giannini, Giuseppe; Gulino, Alberto; Maria I., Achatz; Dirce M., Carraro; B. B., De Paillerets; Audrey, Remenieras; Cindy, Benson; Silvia, Casadei; Mary Claire, King; Erik, Teugels; Manuel R., Teixeira. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - 127:3(2011), pp. 671-679. [10.1007/s10549-010-1036-3]
International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation
GIANNINI, Giuseppe;GULINO, Alberto;
2011
Abstract
The c.156_157insAlu BRCA2 mutation has so far only been reported in hereditary breast/ovarian cancer (HBOC) families of Portuguese origin. Since this mutation is not detectable using the commonly used screening methodologies and must be specifically sought, we screened for this rearrangement in a total of 5,443 suspected HBOC families from several countries. Whereas the c.156_157insAlu BRCA2 mutation was detected in 11 of 149 suspected HBOC families from Portugal, representing 37.9% of all deleterious mutations, in other countries it was detected only in one proband living in France and in four individuals requesting predictive testing living in France and in the USA, all being Portuguese immigrants. After performing an extensive haplotype study in carrier families, we estimate that this founder mutation occurred 558 +/- A 215 years ago. We further demonstrate significant quantitative differences regarding the production of the BRCA2 full length RNA and the transcript lacking exon 3 in c.156_157insAlu BRCA2 mutation carriers and in controls. The cumulative incidence of breast cancer in carriers did not differ from that of other BRCA2 and BRCA1 pathogenic mutations. We recommend that all suspected HBOC families from Portugal or with Portuguese ancestry are specifically tested for this rearrangement.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
